Labetuzumab govitecan-5 mg

Description
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. |[2]Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. |[3]Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. -CASNumber-1469876-18-3-MolecularWeight-154000 (average)-Compound Purity-98.33-SMILES-[Labetuzumab govitecan]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related